Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men
Sponsored by Nihon Pharmaceutical Co., Ltd
About this trial
Last updated 15 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Trial Timing
Ended 16 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
Healthy adult male volunteers who meet all the following criteria will be enrolled in the study. Subjects have to provide written informed consent for voluntary participation in the study. 1. Volunteers who are in good health as confirmed by the investigator or subinvestigator 2. Volunteers (age from 35 to less than 65 years old at the time of consent)
Exclusion Criteria
Volunteers who meet any of the following criteria will be excluded from the study. 1. Volunteers with any clinically significant symptoms, physical findings or laboratory values at screening visit which are considered unsuitable for participation in the study in the investigator's or subinvestigator's opinion 2. Volunteers with a history of surgery in the upper gastrointestinal tract 3. Volunteers with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil) 4. Volunteers with a history of shock or hypersensitivity to scopolamine butylbromide, glucagon, lidocaine hydrochloride or heparin sodium 5. Volunteers who are contraindicated for administration of scopolamine butylbromide or glucagon in the investigator's or subinvestigator's opinion based on health interview 6. Volunteers who have been exposed to NPO-11 7. Volunteers who have received other investigational drugs within four months before consent or who are participating in other clinical studies 8. Volunteers otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion